← back to search

Jessica Philpott

University of Manitoba · CA
Area of research
Genetics · Epidemiology
Research interest
Research focused on Pouch and Crohn's disease, with related work in Proctocolectomy, Pouchitis, Interquartile range. Notable publications include 'Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis', 'Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium', and 'Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium'.
h-index
citations
569
works
7
NIH funding
primary concept
email

Recent publications

Management of pouch neoplasia: consensus guidelines from the International Ileal Pouch Consortium
˜The œLancet. Gastroenterology & hepatology 2022cited by 31position: middledoi
Mild neoterminal ileal post‐operative recurrence of Crohn’s disease conveys higher risk for severe endoscopic disease progression than isolated anastomotic lesions
Alimentary Pharmacology & Therapeutics 2022cited by 29position: middledoi
Intra-abdominal septic complications after ileocolic resection increases risk for endoscopic and surgical postoperative Crohn’s disease recurrence
Journal of Crohn s and Colitis 2022cited by 17position: middledoi
Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium
˜The œLancet. Gastroenterology & hepatology 2021cited by 153position: middledoi
Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium
˜The œLancet. Gastroenterology & hepatology 2021cited by 113position: middledoi
Test Characteristics of Cross-sectional Imaging and Concordance With Endoscopy in Postoperative Crohn’s Disease
Clinical Gastroenterology and Hepatology 2021cited by 30position: middledoi
Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis
Journal of Clinical Oncology 2019cited by 196position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Jordan E. Axelrad · NYU Langone Health3 papers (2021–2022) · 3 papers (2021–2022)Amy L. Lightner · Scripps Research Institute3 papers (2021–2022) · 3 papers (2021–2022)Salam Bachour · Case Western Reserve University3 papers (2021–2022)Florian Rieder · Cleveland Clinic3 papers (2021–2022)Ravi S. Shah · Houston Methodist3 papers (2021–2022)Taha Qazi · Cleveland Clinic3 papers (2021–2022)Stefan D. Holubar · Cleveland Clinic3 papers (2021–2022)Benjamin Click · University of Colorado Denver3 papers (2021–2022)Edward L. Barnes · University of North Carolina at Chapel Hill3 papers (2021–2022)Miguel Regueiro · Cleveland Clinic2 papers (2021–2022)Ruishen Lyu · Cleveland Clinic Lerner College of Medicine2 papers (2021–2022)Benjamin L. Cohen · Cleveland Clinic Florida2 papers (2021–2022) · 1 papers (2019–2019)Miguel Regueiro · Cleveland Clinic1 papers (2022–2022)Abdul Rafeh Naqash · Oklahoma City University1 papers (2019–2019)Dwight H. Owen · Columbus Oncology and Hematology Associates1 papers (2019–2019)Jiajia Zhang · Tongji University1 papers (2019–2019)Yinghong Wang · The University of Texas MD Anderson Cancer Center1 papers (2019–2019)